- ICH GCP
- US Clinical Trials Registry
- Search trials
Search clinical trials for: ADP receptor inhibitors
Total 76936 results
-
Institute of Cancer Research, United KingdomAstraZeneca; Cancer Research UKRecruitingGynaecological CancersUnited Kingdom
-
University of UtahClovis Oncology, Inc.Terminated
-
Mario Negri Institute for Pharmacological ResearchNorth Eastern German Society of Gynaecological OncologyActive, not recruitingOvarian Cancer | Fallopian Tube Cancer | Primary Peritoneal CarcinomaItaly, Germany
-
Dana-Farber Cancer InstituteTesaro, Inc.Active, not recruiting
-
Matthew GalskyIcahn School of Medicine at Mount Sinai; AstraZenecaCompletedMetastatic Urothelial CancerUnited States
-
AstraZenecaCompletedBRCA or HRR+ Mutated Ovarian Cancer PatientsItaly, Spain, Canada, Czechia, Poland, United Kingdom, Hungary, Bulgaria
-
PfizerTerminated
-
UNICANCERClovis Oncology, Inc.; Fondation ARCCompletedMetastatic Breast CancerFrance
-
AstraZenecaNo longer availablePSR Ovarian Cancer With a BRCA MutationJapan
-
Gustave Roussy, Cancer Campus, Grand ParisUnknownNon Small Cell Lung CancerFrance
-
Dana-Farber Cancer InstituteWithdrawnOvarian Cancer | Fallopian Tube Cancer | Peritoneal CancerUnited States
-
University of WashingtonAstraZenecaTerminatedCastration-Resistant Prostate Carcinoma | Prostate AdenocarcinomaUnited States
-
University of Alabama at BirminghamTerminatedOvarian Cancer | Resistant BRCA Wild-Type Ovarian CancerUnited States
-
German Breast GroupGlaxoSmithKline; Stemline Therapeutics, Inc.Not yet recruitingBRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | Hormone Receptor Positive HER-2 Negative Breast Cancer | Advanced or Metastatic Breast CancerGermany
-
National Taiwan University HospitalAstraZenecaRecruiting
-
Sun Yat-sen UniversityRecruitingNasopharyngeal CarcinomaChina
-
Gruppo Oncologico del Nord-OvestRecruitingHead and Neck Squamous Cell CarcinomaItaly
-
National Cancer Institute, NaplesRecruitingBRCA Wild Type Platinum Sensitive Recurrent Ovarian CancerItaly
-
Peter MacCallum Cancer Centre, AustraliaRecruitingMetastatic Castration Resistant Prostate Cancer (mCRPC)Australia
-
National Cancer Institute (NCI)RecruitingLung Neoplasms | Small Cell Lung Cancer | Prostate Cancer | Urothelial Carcinoma | Urothelial CancerUnited States
-
Tango Therapeutics, Inc.TerminatedBreast Cancer | Ovarian Cancer | Prostate Cancer | Pancreas Cancer | BRCA1 Mutation | BRCA-Mutated Ovarian Carcinoma | BRCA-Associated Breast Carcinoma | HRD Positive Advanced Ovarian CancerUnited States
-
BayerGlaxoSmithKlineTerminatedOvarian Cancer | Advanced Solid Tumors (Excluding Prostate Cancer)United States
-
Sheba Medical CenterCompleted
-
Institut BergoniéNational Cancer Institute, FranceCompleted
-
PfizerMedivation, Inc.Completed
-
AstraZenecaParexelApproved for marketing
-
Abramson Cancer Center at Penn MedicineActive, not recruitingAdvanced Breast Cancer | Metastatic Breast Cancer | BRCA1 Mutation | BRCA2 Mutation | Locally Advanced Breast CancerUnited States
-
Vejle HospitalAbbottCompletedOvarian CancerDenmark
-
National Cancer Institute (NCI)WithdrawnRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Ovarian Serous Adenocarcinoma | Primary Peritoneal... and other conditions
-
ExelixisRecruitingAdvanced Solid TumorUnited States
-
Massachusetts General HospitalGlaxoSmithKlineRecruitingMetastatic Cancer | Central Nervous System CancerUnited States
-
AstraZenecaActive, not recruitingBreast | Prostate | Ovarian | Pancreatic | Advanced TumoursSweden, Spain, Israel, Australia, Germany
-
Jiangsu HengRui Medicine Co., Ltd.Terminated
-
Haihe Biopharma Co., Ltd.TerminatedBreast Cancer | Ovarian Cancer | Solid Tumor | Prostate Cancer | Endometrial CancerUnited States, Australia, China
-
Abramson Cancer Center at Penn MedicineActive, not recruitingProstate AdenocarcinomaUnited States
-
GlaxoSmithKlineSuspendedNeoplasmsGermany, Spain, United Kingdom, France, Hungary, Czechia
-
Sarah E TaylorAmerican Society of Clinical OncologyTerminatedOvarian CancerUnited States
-
Arcagy ResearchBelgian Gynaecological Oncology Group; Grupo Español de Investigación en Cáncer... and other collaboratorsCompletedOvarian CancerFrance, Germany, Austria, Denmark, Italy, Japan, Finland, Spain, Monaco, Sweden, Belgium
-
AbbVieNo longer availableHigh Grade Serous Ovarian Cancer | Solid Tumors With Documented BRCA, BARD, or PALB or Other Acceptable DNA Mutations or Anomalies That Are Scientifically Sound | Triple Negative Breast Cancer (TNBC) | Patients Requiring Veliparib Suspension Formulation
-
Grupo Español de Investigación en Cáncer de OvarioCompletedFallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal CancerSpain
-
National Cancer Institute (NCI)Completed
-
National Cancer Institute (NCI)CompletedAdvanced Breast Cancer | Advanced Solid Tumors | Primary Peritoneal Cancer | Advanced Ovarian CancerUnited States
-
Jihong LiuUnknownPlatinum-resistant Ovarian CancerChina
-
Laval UniversityTerminated
-
National Cancer Institute (NCI)CompletedBreast Cancer | Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer | Primary Peritoneal CancerUnited States
-
Institute of Cancer Research, United KingdomRoyal Marsden NHS Foundation TrustUnknownAdenocarcinoma of the ProstateUnited Kingdom
-
PfizerCompleted
-
Massachusetts General HospitalCompleted
-
Tesaro, Inc.WithdrawnLymphoma | Mantle-Cell
-
PfizerWithdrawnDiabetes Mellitus | Diabetic Retinopathy